Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADTX NASDAQ:SCPS NASDAQ:SYRS NASDAQ:VINC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$0.01-29.7%$5.94$0.01▼$53,451.08$20K0.8447.27 million shs624.52 million shsSCPSScopus BioPharma$0.00-33.3%$0.00$0.00▼$0.01$17K-0.143,497 shs900 shsSYRSSyros Pharmaceuticals$0.00-50.0%$0.00$0.00▼$0.04$3K1.3117,673 shs230 shsVINCVincerx Pharma$0.01$0.01$0.00▼$0.07$69K1.464,799 shs437 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt-35.99%-80.51%-99.37%-99.98%-100.00%SCPSScopus BioPharma0.00%-33.33%-33.33%0.00%+33.33%SYRSSyros Pharmaceuticals0.00%-75.00%-50.00%-50.00%-99.60%VINCVincerx Pharma0.00%+3.15%+1.55%+3.97%-74.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$0.01-29.7%$5.94$0.01▼$53,451.08$20K0.8447.27 million shs624.52 million shsSCPSScopus BioPharma$0.00-33.3%$0.00$0.00▼$0.01$17K-0.143,497 shs900 shsSYRSSyros Pharmaceuticals$0.00-50.0%$0.00$0.00▼$0.04$3K1.3117,673 shs230 shsVINCVincerx Pharma$0.01$0.01$0.00▼$0.07$69K1.464,799 shs437 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt-35.99%-80.51%-99.37%-99.98%-100.00%SCPSScopus BioPharma0.00%-33.33%-33.33%0.00%+33.33%SYRSSyros Pharmaceuticals0.00%-75.00%-50.00%-50.00%-99.60%VINCVincerx Pharma0.00%+3.15%+1.55%+3.97%-74.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADTXAditxt 1.00SellN/AN/ASCPSScopus BioPharma 0.00N/AN/AN/ASYRSSyros Pharmaceuticals 0.00N/AN/AN/AVINCVincerx Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ADTX, VINC, SCPS, and SYRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026ADTXAditxt Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADTXAditxtN/AN/AN/AN/A$259.70 per shareN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/ASYRSSyros Pharmaceuticals$386K0.01N/AN/A$0.79 per share0.00VINCVincerx PharmaN/AN/AN/AN/A$10.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADTXAditxt-$41.71M-$100,788.35N/AN/AN/A-360,152.50%-374.60%-105.93%N/ASCPSScopus BioPharma-$11.61MN/AN/AN/AN/AN/AN/AN/AN/ASYRSSyros Pharmaceuticals-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2026 (Estimated)VINCVincerx Pharma-$40.16M-$5.31N/AN/AN/AN/A-248.33%-132.73%8/7/2026 (Estimated)Latest ADTX, VINC, SCPS, and SYRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2026Q4 2025ADTXAditxtN/A$315,563.31N/A$315,563.00N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADTXAditxtN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADTXAditxtN/A0.060.05SCPSScopus BioPharmaN/AN/AN/ASYRSSyros PharmaceuticalsN/A2.252.25VINCVincerx PharmaN/A2.172.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADTXAditxt15.54%SCPSScopus BioPharmaN/ASYRSSyros Pharmaceuticals91.47%VINCVincerx Pharma44.02%Insider OwnershipCompanyInsider OwnershipADTXAditxt0.01%SCPSScopus BioPharma5.10%SYRSSyros Pharmaceuticals12.26%VINCVincerx Pharma15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADTXAditxt60820,000816,000No DataSCPSScopus BioPharma942.08 million39.94 millionNot OptionableSYRSSyros Pharmaceuticals12026.83 million23.54 millionNo DataVINCVincerx Pharma605.23 million1.89 millionNot OptionableADTX, VINC, SCPS, and SYRS HeadlinesRecent News About These CompaniesAntibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 DrugsApril 14, 2026 | finance.yahoo.comContrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)January 18, 2026 | defenseworld.netDVincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...July 16, 2025 | gurufocus.comVincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution ProposalJuly 16, 2025 | globenewswire.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila TimesJuly 9, 2025 | manilatimes.netMVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - MorningstarJuly 9, 2025 | morningstar.comMVincerx Pharma, Inc. Common Stock (VINC) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to StockholdersJuly 7, 2025 | globenewswire.comVincerx Pharma, Inc. (VINC) - Yahoo FinanceJuly 2, 2025 | ca.finance.yahoo.comVincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution ProposalJune 18, 2025 | globenewswire.comVincerx Pharma announces plan to delist from NasdaqApril 18, 2025 | markets.businessinsider.comVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECApril 17, 2025 | finance.yahoo.comVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECApril 17, 2025 | globenewswire.comVincerx's final merger attempt collapses, leaving ADC biotech to wind downApril 9, 2025 | fiercebiotech.comFVincerx terminates letter of intent with Global Digital, initiates wind downApril 9, 2025 | markets.businessinsider.comFinancially struggling drugmaker's potential rescue falls apart. It now will wind downApril 9, 2025 | bizjournals.comVincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down ActivitiesApril 8, 2025 | globenewswire.comVincerx Pharma announces non-binding LOI for Qumulus AI combinationMarch 18, 2025 | markets.businessinsider.comVincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | finanznachrichten.deVincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisisMarch 18, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADTX, VINC, SCPS, and SYRS Company DescriptionsAditxt NASDAQ:ADTX$0.01 -0.01 (-29.73%) Closing price 04:00 PM EasternExtended Trading$0.02 +0.00 (+17.69%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Scopus BioPharma NASDAQ:SCPS$0.0004 0.00 (-33.33%) As of 02:40 PM EasternScopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.Syros Pharmaceuticals NASDAQ:SYRS$0.0001 0.00 (-50.00%) As of 12:21 PM EasternSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Vincerx Pharma NASDAQ:VINC$0.01 0.00 (0.00%) As of 01:06 PM EasternVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore SpaceX IPO Fears Are Overblown, But the AI Bet Is Real The Biggest Opportunity From SpaceX’s IPO May Surprise You NVIDIA’s Outlook Gains Momentum: Stock Price to Follow Chewy’s Growth Engine Is Stronger Than the Market Thinks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
